This inventor holds 2 USPTO granted patents and 1 published patent application, plus 2 CIPO patents and 2 EPO patents. Top assignees: Tianjin Chase Sun Pharmaceutical Co., Ltd, The First Affiliated Hospital, Third Military Medical University, Pla, The First Affiliated Hospital, Third Military University, Pla. Active years: 2016-2018.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
2 out of 7 
1 out of 1 
1 out of 1 Years Active: 2016-2018
Title: Innovations by Hongwei Cao in the Field of Medicine
Introduction
Hongwei Cao is a notable inventor based in Chongqing, China. He has made significant contributions to the field of medicine, particularly in the development of drugs aimed at preventing and treating sepsis and autoimmune diseases. With a total of 2 patents, his work focuses on utilizing traditional Chinese medicine to address critical health challenges.
Latest Patents
Cao's latest patents include the use of Kukoamine A and Kukoamine B. This patent discloses the application of these compounds in the preparation of drugs for the prevention and treatment of sepsis and autoimmune diseases. The invention specifically targets bacterial endotoxin/lipopolysaccharide (LPS) and unmethylated DNA (CpG DNA), which are major pathogen-associated molecular patterns in these conditions. By isolating lead compounds from traditional Chinese medicine, this approach aims to overcome the uncertainties associated with pharmacological material bases and drug targets. The disclosed use can significantly contribute to developing safe, effective, and quality-controllable drugs for these medical conditions.
Another patent focuses on the salts of Kukoamine B, detailing their preparation method and pharmaceutical use in drug formulation for sepsis prevention and treatment. Experimental results indicate that these salts effectively antagonize key factors inducing sepsis. This innovation provides a new approach to addressing the current lack of effective treatments in clinical practice.
Career Highlights
Throughout his career, Hongwei Cao has worked with various organizations, including Tianjin Chase Sun Pharmaceutical Co., Ltd and the First Affiliated Hospital, Third Military Medical University. His experience in these institutions has allowed him to contribute to significant advancements in pharmaceutical research and development.
Collaborations
Cao has collaborated with notable colleagues such as Jiang Zheng and Xin Liu. These partnerships have facilitated the exchange of ideas and expertise, further enhancing the impact of his innovations in the medical field.
Conclusion
Hongwei Cao's contributions to medicine through his patents on Kukoamine A and B represent a significant advancement in the prevention and treatment of sepsis and autoimmune diseases. His work exemplifies the potential of traditional Chinese medicine in modern pharmaceutical applications.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile